Post on 30-Jul-2020
METAL IONS INBIOLOGICAL SYSTEMS
Astrid SigelHelmut Sige l
VOLUME 42
Metal Complexes in Tumor Diagnosi sand as Anticancer Agents
PREFACE TO THE SERIE S
PREFACE TO VOLUME 42
v
CONTRIBUTORS
xv
CONTENTS OF PREVIOUS VOLUMES
xix
HANDBOOK ON TOXICITY OF INORGANIC COMPOUNDS liv
HANDBOOK ON METALS IN CLINICAL AND
liv
ANALYTICAL CHEMISTRY
HANDBOOK ON METALLOPROTEINS
liv
Chapter 1
MAGNETIC RESONANCE CONTRAST AGENTS FOR MEDICA L
AND MOLECULAR IMAGING
1
Matthew J. Allen and Thomas J. Meade1. Introduction
2
2. Contrast Agents for Diagnosis
5
3. Targeted Delivery of Contrast Agents
1 1
4. Imaging Biochemical Events
1 4
5. Conclusions and Outlook
26
Acknowledgments
26
Abbreviations
26
References
28
Chapter 2
LUMINESCENT LANTHANIDE PROBES AS DIAGNOSTI C
AND THERAPEUTIC TOOLS
3 9
Jean-Claude G . Bünzl i1 . Lanthanide-Based Luminescent Probes : Why?
40
2. Designing a Lanthanide-Based Luminescent Probe
443. Applications in Medical Diagnosis
574. Use of Lanthanide Complexes in Photodynamic Therapies
655. Concluding Remarks
70Acknowledgments
7 1Abbreviations
7 1References
72
Chapter 3RADIOLANTHANIDES IN NUCLEAR MEDICINE
77Frank Rösch and Eva Forssell-Aronsson1. Introduction
782. Radiolanthanide Production
793. Labelling Chemistry and Labelled Compounds
82
4. Application of Radiolanthanide Radiopharmaceuticals
845. Conclusion
99Abbreviations
100References
10 1
Chapter 4RADIOMETALLO-LABELED PEPTIDES IN TUMOR DIAGNOSI SAND THERAPY
109Mihaela Ginj and Helmut R . Maecke1. Introduction
11 02. Radiometals of Interest for Peptide Labeling and Labelin g
Approaches
11 63. In Vitro Characterization of Radiometallo-Peptides
1244. Animal Models to Study Targeting of Tumors . Biodistribution
Therapy Studies
12 85. Influence of the (Radio)Metal Ion and Its Coordinatio n
Chemistry on the Targeting Properties of Radiometallo-Peptides 13 06. Overview of Patient Studies
13 37. Summary and Conclusion
13 7Abbreviations
13 7References
139
Chapter 5CISPLATIN AND RELATED ANTICANCER DRUGS :RECENT ADVANCES AND INSIGHTS
143Katie R . Barnes and Stephen J. Lippard1. Introduction
1442. Mechanism of Action
1453. Cellular Defenses Against Cisplatin
1604. Novel C-isplatinum Analogs as Anticancer Compounds
1635. Conclusions and Future Directions
167Acknowledgment
168Abbreviations
168References
169
Chapter 6THE EFFECT OF CYTOPROTECTIVE AGENTS I NPLATINUM ANTICANCER THERAPY
179Michael A. Jakupec, Markus Galanski, and Bernhard K. Keppler1. Toxicity Associated with Platinum Anticancer Therapy
1792. Overview of Cytoprotective Approaches
18 33. Amifostine
1864. Glutathione
1905. BNP7787 (Dimesna)
1946. a-Tocopherol (Vitamin E)
1957. a-Lipoic Acid
1968. Concluding Remarks
196Abbreviations
198References
198
Chapter 7ANTITUMOR ACTIVE TRANS-PLATINUM COMPOUNDS
209Giovanni Natile and Mauro Colucci a1. Introduction
21 02. Antitumor Active Trans-Platinum Compounds
22 13. Conclusions and Perspectives
23 9Acknowledgments
241Abbreviations and Definitions
241References
242
Chapter 8
POLYNUCLEAR PLATINUM DRUGS
25 1
Nicholas Farrel l
1. Introduction
252
2. Structural Variations within Polynuclear Platinum Complexes
25 3
3. DNA Binding Modes of Polynuclear Platinum Drugs
26 1
4. Trifunctional Dinuclear Platinum Complexes . Ternary
DNA-Protein Crosslinking
274
5. Polynuclear Platinum Complexes Bind Faster t o
Single-Stranded DNA
277
6. Biological Activity of Polynuclear Platinum Compounds
282
7. Clinical Experience
28 7
8. Conclusions
28 8
Acknowledgments
289
Abbreviations
290
References
290
Chapter 9
PLATINUM(IV) ANTICANCER COMPLEXES
297
Matthew D . Hall, Rachael C. Dolman, and Trevor W. Hambley
1. Introduction
298
2. History
298
3. Mechanism of Action
300
4. Design
30 1
5. Synthesis
307
6. In Vitro Interactions with Biomolecules
31 0
7. Biological Fate
311
8. Conclusions
31 6
Acknowledgments
31 6
Abbreviations
31 6
References
31 7
Chapter 1 0
RUTHENIUM ANTICANCER DRUGS
323
Enzo Alessio, Giovanni Mestroni, Alberta Bergamo, and Gianni Sav a
I . Introduction
324
2 . Chemical Features
325
3. Pharmacological Control of Tumor Growth
3344. Conclusions
344Acknowledgments
346Abbreviations
346References
347
Chapter 1 1ANTITUMOR TITANIUM COMPOUNDS AND RELATEDMETALLOCENES
353Francesco Caruso and Miriam Rossi1. Introduction
3542. Evolution of Titanium Drugs in Physiological Medium
3583. Potential Targets
3604. Attachment to Carriers
3625. Structure-Activity Studies
3626. Phase II Clinical Trials of Titanocene Dichloride
3687. Non-Titanium Metallocenes
3698. Conclusions Regarding Titanium-Based Antitumor Drugs
376Acknowledgments
378Abbreviations and Definitions
378References
379
Chapter 1 2GOLD COMPLEXES AS ANTITUMOR AGENTS
385Luigi Messori and Giordana Marco n1. Introduction
3862. Main Chemical Features of Gold Complexes
3883. Gold(I) Complexes as Antitumor Agents
3904. Gold(III) Complexes as Antitumor Agents
3995. Conclusions and Perspectives
41 9Acknowledgments
420Abbreviations
420References
421
Chapter 1 3GALLIUM AND OTHER MAIN GROUP METAL COMPOUND SAS ANTITUMOR AGENTS
425Michael A . Jakupec and Bernhard K. Keppler
1. Introduction
4262. "Simple Gallium Salts"
4273. Gallium Complexes
44 14. Other Main Group Metal Compounds in Cancer Therapy
4485. Summary and Conclusions
449Abbreviations
45 1References
45 1
Chapter 1 4METAL ION DEPENDENT ANTIBIOTICS I NCHEMOTHERAPY
463David H. Petering, Chuanwu Xia, and William E. Antholine
1. Introduction
4642. Direct Requirements of Antibiotics for Metal Ions : Mechanism 46 8
of Action of Bleomyci n3. Indirect Requirements of Antibiotics for Metal Ions : Mechanism 47 8
of Action of Doxorubicin4. Survey of Metal-Linked Antibiotics
4855. Discussion
488Acknowledgments
48 8Abbreviations and Definitions
488References
489
SUBJECT INDEX
499